1
|
Troya J, Pousada G, Micán R, Galera C, Sanz J, de Los Santos I, Dueñas C, Cabello N, Martín C, Galindo MJ, Garcinuño MÁ, Pedrero-Tomé R, Buzón L. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study. J Antimicrob Chemother 2024; 79:595-607. [PMID: 38267266 DOI: 10.1093/jac/dkae011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Accepted: 01/04/2024] [Indexed: 01/26/2024] Open
Abstract
BACKGROUND Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed. METHODS We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF. We evaluated CD4+, CD8+ and CD4+/CD8+ ratio, efficacy and safety at weeks 48 and 96. RESULTS The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0-57.0] years. The median time of HIV infection was 18.0 [10.0-27.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+/CD8+ were observed after 96 weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients ≥60 years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA <50 copies/mL in 95.6% (1700/1779) and 96.7% (1312/1356) of patients at weeks 48 and 96, respectively. The rates increased to 99.2% (1765/1779) and 99.7% (1352/1356) when considering HIV-RNA <200 copies/mL. No resistance mutations were detected in virologic failures. B/F/TAF discontinuations accounted for 10.2% (200). Simplification was the most common reason for discontinuation in 3.8% (74) of patients. CONCLUSION In long-term virologically controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching.
Collapse
Affiliation(s)
- Jesús Troya
- Department of Infectious Diseases, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Guillermo Pousada
- Department of Infectious Diseases, Hospital Álvaro Cunqueiro, Vigo, Spain
| | - Rafael Micán
- Department of Infectious Diseases, Hospital Universitario La Paz, Madrid, Spain
| | - Carlos Galera
- Department of Infectious Diseases, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
| | - José Sanz
- Department of Infectious Diseases, Hospital Príncipe de Asturias, Alcalá de Henares, Spain
| | - Ignacio de Los Santos
- Department of Infectious Diseases, Hospital Universitario La Princesa, Madrid, Spain
- CIBERINFEC Instituto de Salud Carlos III, Madrid, Spain
| | - Carlos Dueñas
- Department of Infectious Diseases, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Noemí Cabello
- Department of Infectiosu Diseases, Hospital Clínico San Carlos, Madrid, Spain
| | - Cristina Martín
- Department of Infectious Diseases, Complejo Asistencial de Zamora, Zamora, Spain
| | - María Josefa Galindo
- Department of Infectious Diseases, Hospital Clínico de Valencia, Valencia, Spain
| | | | - Roberto Pedrero-Tomé
- Fundación de Investigación e Innovación Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Luis Buzón
- Department of Infectious Diseases, Hospital de Burgos, Burgos, Spain
| |
Collapse
|
2
|
Homen-Fernandez JR, Valls A, García A, Cabello N, Ortega I, Orviz E, Foncubierta C, Martínez M, Estrada V. Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2. Front Immunol 2023; 14:1267991. [PMID: 37908351 PMCID: PMC10613978 DOI: 10.3389/fimmu.2023.1267991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 09/25/2023] [Indexed: 11/02/2023] Open
Abstract
The SARS-CoV-2 variants demonstrate diverse transmission patterns, modifications in infectivity, and immune response. Changes in disease manifestation may be attributed to vaccination and the virus's reduced capacity to induce inflammation. Objectives To investigate the relationship between the inflammatory response and the characteristics of COVID-19 across successive waves. Methods A retrospective cross-sectional study was conducted to evaluate sociodemographic, clinical, and laboratory data of Alpha (G1), Delta (G2), and Omicron (G3) variants. Results A total of 300 patients from a hospital in Madrid, Spain, were included. The groups exhibited similar sociodemographic and baseline characteristics. The Alpha variant predominantly affected younger patients, while the Omicron variant affected patients with a higher prevalence of comorbidities. The Alpha group had the lowest vaccination rate compared to the highest rate in the Omicron group. The Alpha group received a higher proportion of tocilizumab compared to the other groups. Despite these differences, the severity scores were similar among the three variants. Regarding laboratory parameters, differences were observed in haemoglobin, D-dimer, alkaline phosphatase, and potassium levels. The Omicron variant showed higher D-dimer levels (p=0.04). In the multivariate analysis, differences in leukocyte count, haemoglobin, alkaline phosphatase, and potassium levels were consistently observed among patients from different waves. Omicron exhibited a higher absolute leukocyte count than the Alpha variant (p=0.003). Conclusion No significant differences were found in inflammation biomarkers among the three variants. Furthermore, there were no significant disparities in mortality or disease severity. The level of inflammatory response in patients may be determined by the severity of COVID-19, rather than the specific viral variant.
Collapse
Affiliation(s)
- Jose-Reynaldo Homen-Fernandez
- Servicio de Enfermedades Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain
| | - Adrián Valls
- Servicio de Enfermedades Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain
| | - Ana García
- Servicio de Análisis Clínicos, Instituto de Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain
| | - Noemí Cabello
- Servicio de Enfermedades Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Ortega
- Servicio de Análisis Clínicos, Instituto de Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain
| | - Eva Orviz
- Servicio de Enfermedades Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain
- Centro Sanitario Sandoval, Hospital Clínico San Carlos, Madrid, Spain
| | - Carlos Foncubierta
- Servicio de Análisis Clínicos, Instituto de Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain
| | - Mercedes Martínez
- Servicio de Análisis Clínicos, Instituto de Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain
| | - Vicente Estrada
- Servicio de Enfermedades Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
3
|
Mohamed KM, Guevara-Hoyer K, García CJ, Bravo LG, Jiménez-Huete A, de la Peña AR, Valeros BM, Velázquez CC, López EC, Cabello N, Estrada V, Corbí ÁL, Fernández-Arquero M, Ocaña A, Delgado-Iribarren A, Martínez-Novillo M, Bolaños E, Anguita E, Peña A, Benavente C, Benítez Fuentes JD, Pérez Segura P, Sánchez-Ramón S. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors. Biomedicines 2023; 11:biomedicines11041042. [PMID: 37189660 DOI: 10.3390/biomedicines11041042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 03/14/2023] [Accepted: 03/24/2023] [Indexed: 03/30/2023] Open
Abstract
Patients with antibody deficiency disorders, such as primary immunodeficiency (PID) or secondary immunodeficiency (SID) to B-cell lymphoproliferative disorder (B-CLPD), are two groups vulnerable to developing the severe or chronic form of coronavirus disease caused by SARS-CoV-2 (COVID-19). The data on adaptive immune responses against SARS-CoV-2 are well described in healthy donors, but still limited in patients with antibody deficiency of a different cause. Herein, we analyzed spike-specific IFN-γ and anti-spike IgG antibody responses at 3 to 6 months after exposure to SARS-CoV-2 derived from vaccination and/or infection in two cohorts of immunodeficient patients (PID vs. SID) compared to healthy controls (HCs). Pre-vaccine anti-SARS-CoV-2 cellular responses before vaccine administration were measured in 10 PID patients. Baseline cellular responses were detectable in 4 out of 10 PID patients who had COVID-19 prior to vaccination, perceiving an increase in cellular responses after two-dose vaccination (p < 0.001). Adequate specific cellular responses were observed in 18 out of 20 (90%) PID patients, in 14 out of 20 (70%) SID patients and in 74 out of 81 (96%) HCs after vaccination (and natural infection in some cases). Specific IFN-γ response was significantly higher in HC with respect to PID (1908.5 mUI/mL vs. 1694.1 mUI/mL; p = 0.005). Whereas all SID and HC patients mounted a specific humoral immune response, only 80% of PID patients showed positive anti-SARS-CoV-2 IgG. The titer of anti-SARS-CoV-2 IgG was significantly lower in SID compared with HC patients (p = 0.040), without significant differences between PID and HC patients (p = 0.123) and between PID and SID patients (p =0.683). High proportions of PID and SID patients showed adequate specific cellular responses to receptor binding domain (RBD) neoantigen, with a divergence between the two arms of the adaptive immune response in PID and SID patients. We also focused on the correlation of protection of positive SARS-CoV-2 cellular response to omicron exposure: 27 out of 81 (33.3%) HCs referred COVID-19 detected by PCR or antigen test, 24 with a mild course, 1 with moderate symptoms and the remaining 2 with bilateral pneumonia that were treated in an outpatient basis. Our results might support the relevance of these immunological studies to determine the correlation of protection with severe disease and for deciding the need for additional boosters on a personalized basis. Follow-up studies are required to evaluate the duration and variability in the immune response to COVID-19 vaccination or infection.
Collapse
Affiliation(s)
- Kauzar Mohamed Mohamed
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Kissy Guevara-Hoyer
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
- Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, 28040 Madrid, Spain
| | - Carlos Jiménez García
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Laura García Bravo
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | | | - Antonia Rodríguez de la Peña
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Beatriz Mediero Valeros
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Cristina Cañizares Velázquez
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Esther Culebras López
- Department of Microbiology, IML and IdISSC, Hospital Clínico San Carlos, 28040 Madrid, Spain
| | - Noemí Cabello
- Unit of Infectious Diseases, Department of Internal Medicine, Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Vicente Estrada
- Unit of Infectious Diseases, Department of Internal Medicine, Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Ángel L Corbí
- Centro de Investigaciones Biológicas (CSIC), C./Ramiro de Maeztu, 9, 28040 Madrid, Spain
| | - Miguel Fernández-Arquero
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
- Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, 28040 Madrid, Spain
| | - Alberto Ocaña
- Department of Microbiology, IML and IdISSC, Hospital Clínico San Carlos, 28040 Madrid, Spain
| | | | - Mercedes Martínez-Novillo
- Clinical Analysis Department, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Estefanía Bolaños
- Department of Hematology, Hospital Clínico San Carlos, IML, IdISSC, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Eduardo Anguita
- Department of Hematology, Hospital Clínico San Carlos, IML, IdISSC, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Ascensión Peña
- Department of Hematology, Hospital Clínico San Carlos, IML, IdISSC, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Celina Benavente
- Department of Hematology, Hospital Clínico San Carlos, IML, IdISSC, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Javier David Benítez Fuentes
- Department of Medical Oncology, Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Pedro Pérez Segura
- Department of Medical Oncology, Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| | - Silvia Sánchez-Ramón
- Department of Immunology, Laboratory Medicine Institute (IML) and Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
- Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, 28040 Madrid, Spain
- Department of Clinical Immunology, Hospital Universitario Clínico San Carlos and IdISSC, Calle Profesor Martín Lagos SN, 28040 Madrid, Spain
| |
Collapse
|
4
|
Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, de Orueta LF, Torralba M, Fortún J, Vates R, Barberán J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijón P, Monereo A, Abad D, Zúñiga S, Sola I, Rodon J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Girón de Velasco P, Sopesén B, Nieto A, Gómez J, Avilés P, Lubomirov R, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, Enjuanes L, Fernández-Sousa JM, Krogan NJ, Jimeno JM, García-Sastre A. Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. medRxiv 2021:2021.05.25.21257505. [PMID: 34075384 PMCID: PMC8168388 DOI: 10.1101/2021.05.25.21257505] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.5 mg/day for 3 days, as a 90-minute intravenous infusion) in 45 patients (15 per dose-cohort). Treatment was well tolerated, with only two Grade 3 treatment-related adverse events observed (hypersensitivity and diarrhea). The discharge rates by Days 8 and 15 were 56.8% and 81.8%, respectively, with data sustaining dose-effect. A mean 4.2 log10 viral load reduction was attained by Day 15. Improvement in inflammation markers was also noted in a seemingly dose-dependent manner. These results suggest that plitidepsin impacts the outcome of patients with COVID-19. ONE-SENTENCE SUMMARY Plitidepsin, an inhibitor of SARS-Cov-2 in vitro , is safe and positively influences the outcome of patients hospitalized with COVID-19.
Collapse
|
5
|
Estrada V, Santiago E, Cabezas I, Cotano JL, Carrió JC, Fuentes-Ferrer M, Vera M, Ayerdi O, Rodríguez C, López L, Cabello N, Núñez MJ, Puerta T, Sagastagoitia I, Del Romero J. Tolerability of IM penicillin G benzathine diluted or not with local anesthetics, or different gauge needles for syphilis treatment: a randomized clinical trial. BMC Infect Dis 2019; 19:883. [PMID: 31646969 PMCID: PMC6813081 DOI: 10.1186/s12879-019-4490-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Accepted: 09/23/2019] [Indexed: 11/25/2022] Open
Abstract
Background Penicillin G Benzathine (PGB) is the cornerstone of syphilis treatment. However, its intramuscular (IM) administration is associated with pain at the site of injection. The dilution of PGB with local anesthetics is recommended in some guidelines, but the evidence that supports it, particularly in adults and in HIV infection, is scarce. Preliminary clinical experience also suggests that the IM administration of PGB through increased needle gauges might improve its tolerability. The aim of the study to identify less painful ways of administering IM PGB in the treatment of syphilis in adults. Methods Multicenter, randomized, double-blinded clinical trial in patients diagnosed with primary syphilis that required a single IM injection of PGB 2400,00 IU. Patients were randomized to receive PGB diluted with 0.5 mL mepivacaine 1% (MV) or PGB alone, and both groups either with a long 19G or short 21G IM needle. The primary objective was the effect on local pain immediately after the administration through a visual scale questionnaire on pain (0 to 10). Results One hundred eight patients were included, 27 in each group. Ninety-four (94.4%) were male, and 41.7% were also HIV-infected. Mean age 36.6 years (SD 11). Significant differences in immediate pain intensity were observed when comparing the long 19G group with anesthesia (mean pain intensity, [MPI] 2.92 [CI 95% 1.08-4.07]) vs long 19G without anesthesia (MPI 5.56 [CI 95% 4.39-6.73), p < 0.001; and also between short 21G group with anesthesia (MPI 3.36 [CI 95% 2.22-4.50]) vs short 21G without anesthesia (MPI 5.06 [CI 95% 3.93-6.19]), p = 0.015). No significant differences in immediate pain were observed between 19G and 21G in the presence or absence of anesthesia (p = 1.0 in both cases). No differences were found between study arms after 6 and 24 h. Conclusions The IM administration of 1% mepivacaine-diluted PGB induces significantly less immediate local pain as compared to PGB alone. The needle gauge did not have any effect on the pain. Based on these results, we suggest anesthetic-diluted IM PGB as the standard treatment for primary syphilis. Trial registration EudraCT 2014-003969-24 (Date of registration 18/09/2014).
Collapse
Affiliation(s)
- Vicente Estrada
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain.
| | - Eva Santiago
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| | | | - Juan Luis Cotano
- Centro Sanitario Sandoval, IdiSSC, C/Sandoval, 7, 28010, Madrid, Spain
| | | | - Manuel Fuentes-Ferrer
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| | - Mar Vera
- Centro Sanitario Sandoval, IdiSSC, C/Sandoval, 7, 28010, Madrid, Spain
| | - Oskar Ayerdi
- Centro Sanitario Sandoval, IdiSSC, C/Sandoval, 7, 28010, Madrid, Spain
| | - Carmen Rodríguez
- Centro Sanitario Sandoval, IdiSSC, C/Sandoval, 7, 28010, Madrid, Spain
| | - Laura López
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| | - Noemí Cabello
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| | - María José Núñez
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| | - Teresa Puerta
- Centro Sanitario Sandoval, IdiSSC, C/Sandoval, 7, 28010, Madrid, Spain
| | - Iñigo Sagastagoitia
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| | - Jorge Del Romero
- Medicina Interna/enfermedades infecciosas, Hospital Clínico San Carlos, IdiSSC, Universidad Complutense, c/Martin Lagos SN, 28040, Madrid, Spain
| |
Collapse
|
6
|
Dorel R, de Mendoza P, Calleja P, Pascual S, González‐Cantalapiedra E, Cabello N, Echavarren AM. Synthesis of a Crushed Fullerene C60H24 through Sixfold Palladium-Catalyzed Arylation. European J Org Chem 2016; 2016:3171-3176. [PMID: 27774038 PMCID: PMC5053240 DOI: 10.1002/ejoc.201600311] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Indexed: 11/11/2022]
Abstract
The synthesis of a new C3v -symmetric crushed fullerene C60H24 (5) has been accomplished in three steps from truxene through sixfold palladium-catalyzed intramolecular arylation of a syn-trialkylated truxene precursor. Laser irradiation of 5 induces cyclodehydrogenation processes that result in the formation of C60, as detected by LDI-MS.
Collapse
Affiliation(s)
- Ruth Dorel
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
| | - Paula de Mendoza
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
| | - Pilar Calleja
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
| | - Sergio Pascual
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
| | - Esther González‐Cantalapiedra
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
| | - Noemí Cabello
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
| | - Antonio M. Echavarren
- Institute of Chemical Research of Catalonia (ICIQ)Barcelona Institute of Science and TechnologyAv. Països Catalans 1643007TarragonaSpain
- Departament de Química Orgànica i AnalíticaUniversitat Rovira i VirgiliC/ Marcel·lí Domingo s/n43007TarragonaSpain
| |
Collapse
|
7
|
Horrillo L, San Martín JV, Molina L, Madroñal E, Matía B, Castro A, García-Martínez J, Barrios A, Cabello N, Arata IG, Casas JM, Ruiz Giardin JM. Atypical presentation in adults in the largest community outbreak of leishmaniasis in Europe (Fuenlabrada, Spain). Clin Microbiol Infect 2014; 21:269-73. [PMID: 25658537 DOI: 10.1016/j.cmi.2014.10.017] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Revised: 10/18/2014] [Accepted: 10/21/2014] [Indexed: 11/27/2022]
Abstract
Since 2009, the largest reported outbreak of leishmaniasis by Leishmania infantum in Europe was reported in Fuenlabrada, Spain. In our hospital, 90 adults with localized leishmanial lymphadenopathy (LLL) or visceral leishmaniasis (VL) were treated during this outbreak; 72% were men, and the mean age was 46.2 years (range 15-95 years). A total of 17 cases (19%) were LLL, an atypical form with isolated lymphadenopathies without other symptoms. All LLL cases occurred in immunocompetent subjects, and only one subject (6%) was a native of sub-Saharan Africa. Diagnosis was performed by fine needle aspiration cytology of the lymphadenopathy. Serology was negative in 38%. LLL outcomes at 6 months were benign, even with doses of liposomal amphotericin B that were often lower (10 mg/kg) than those recommended for VL in Mediterranean areas. A total of 73 subjects (81%) presented with typical VL; 66% of this group were immunocompetent, and 50% of those who were immunocompetent were descendants of natives of sub-Saharan Africa. The rK39 test and polymerase chain reaction were the most useful tests for confirmation of the diagnosis. An initial response to treatment was observed in 99% of cases, and relapses occurred in 14% of cases. Leishmaniasis should be included in the differential diagnosis of isolated lymphadenopathies in endemic areas. LLL could be considered a more benign entity, one different than VL, and less aggressive management should be studied in future investigations.
Collapse
Affiliation(s)
- L Horrillo
- Department of Internal Medicine, Madrid, Spain.
| | - J V San Martín
- Department of Internal Medicine, Madrid, Spain; Infectious Diseases Area, Madrid, Spain
| | - L Molina
- Microbiology Area, Laboratory Medicine Department, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - E Madroñal
- Department of Internal Medicine, Madrid, Spain
| | - B Matía
- Department of Internal Medicine, Madrid, Spain
| | - A Castro
- Department of Internal Medicine, Madrid, Spain
| | - J García-Martínez
- Microbiology Area, Laboratory Medicine Department, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - A Barrios
- Department of Internal Medicine, Madrid, Spain; Infectious Diseases Area, Madrid, Spain
| | - N Cabello
- Department of Internal Medicine, Madrid, Spain; Infectious Diseases Area, Madrid, Spain
| | - I G Arata
- Microbiology Area, Laboratory Medicine Department, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - J M Casas
- Department of Internal Medicine, Madrid, Spain
| | - J M Ruiz Giardin
- Department of Internal Medicine, Madrid, Spain; Infectious Diseases Area, Madrid, Spain
| |
Collapse
|
8
|
Llach A, Rivera J, Herraiz A, Cabello N, Gonzalez C, Vallmitjana A, Benitez R, Andres V, Hove-Madsen L. Abnormal calcium handling in the progeric mouse model Zmpste24-/- is linked to reduced sarcoplasmic reticulum calcium loading and depression of SERCA2 and calsequestrin-2 expression. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Canalejo E, Cabello N, Perales I, Allodi S, Sánchez-Purificación A. Enfermedad arterial periférica asintomática estimada mediante el índice tobillo-brazo en pacientes con infección por el VIH: prevalencia y factores de riesgo asociados. Enferm Infecc Microbiol Clin 2011; 29:672-8. [DOI: 10.1016/j.eimc.2011.07.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2010] [Revised: 06/18/2011] [Accepted: 07/06/2011] [Indexed: 11/17/2022]
|
10
|
Franco AI, Ortiz J, Cabello N, Ruiz Giardin JM, García MI. [Shigella bacteremia dysentery in an adult]. Rev Esp Quimioter 2010; 23:51-52. [PMID: 20232025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
|
11
|
San Martín J, Cabello N, Mateo O, Zapatero A. Réplica. Rev Clin Esp 2008. [DOI: 10.1016/s0014-2565(08)76045-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Cabello N, Jiménez-Núñez E, Buñuel E, Cárdenas DJ, Echavarren AM. On the Mechanism of the Puzzling “Endocyclic” Skeletal Rearrangement of 1,6-Enynes. European J Org Chem 2007. [DOI: 10.1002/ejoc.200700402] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
13
|
Echavarren A, Cabello N, Rodríguez C. Gold-Catalyzed Cyclizations of 1,7-Enynes. Synlett 2007. [DOI: 10.1055/s-2007-985578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
|
15
|
Affiliation(s)
- P Barreiro
- Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
| | | | | | | |
Collapse
|
16
|
Cabello N, Gargantilla P, San Román J, Lázaro C, Santillana T, Orejas B. [Multiple pulmonary nodules and fever in a 35-year-old male]. Enferm Infecc Microbiol Clin 1999; 17:191-2. [PMID: 10365515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Affiliation(s)
- N Cabello
- Servicio de Medicina Interna IV, Hospital Clínico San Carlos, Madrid
| | | | | | | | | | | |
Collapse
|